Efficient Regulatory Publishing For A Large-Scale FDA Submission

Preparing a supplemental New Drug Application (sNDA) can strain even experienced regulatory teams when timelines are tight, and submission volumes are massive. This case study highlights how Veristat helped a commercial-stage biopharmaceutical company successfully deliver a high-volume FDA sNDA for a bipolar disorder indication ahead of schedule.

Building on a previously successful NDA collaboration, Veristat provided integrated regulatory strategy, publishing, and project management support to manage a technically complex submission containing more than 56,000 pages. Learn more about how, despite the 837 MB total submission size, Veristat enabled the company to successfully achieve an early submission, demonstrating how experienced regulatory publishing and cross-functional collaboration help sponsors to navigate complex sNDA milestones with confidence.